21 CFR 520.2700
§ 520.2700 Verdinexor tablets.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 520.2700, § 520.2700 Verdinexor tablets, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87376
- Permanent ID
ys:prov:87376@1- SHA-256
bfcd5b4af7a9cfb942a4322547a753c46f255bcbc02e4720c23c1f338797976e
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications. Each tablet contains 2.5, 10, 22.5, or 50 milligrams (mg) verdinexor.
(b) Sponsor. See No. 043264 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. Administer verdinexor tablets orally at an initial dose of 1.25 mg per kilogram (mg/kg) of body weight twice per week with at least 72 hours between doses. If tolerated after 2 weeks, increase the dose to 1.5 mg/kg twice per week with at least 72 hours between doses.
(2) Indications for use. For the treatment of lymphoma in dogs.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.